[1]
|
Kawasaki, T. (2006) Kawasaki Disease. Proceedings of the Japan Academy, Ser. B, Physical and Biological Science, 82, 59-71. https://doi.org/10.2183/pjab.82.59
|
[2]
|
McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals from the American Heart Association. Circulation, 135, e927-e999. https://doi.org/10.1161/CIR.0000000000000484
|
[3]
|
杜忠东, 陈笑征. 川崎病流行病学研究进展[J]. 中国实用儿科杂志, 2017, 32(8): 565-569.
|
[4]
|
张新艳, 杨婷婷, 何婷, 等. 2012至2016年单中心川崎病流行病学及临床特征研究[J]. 中国循证儿科杂志, 2018, 13(6): 427-432.
|
[5]
|
Pilania, R.K., Bhattarai, D. and Singh, S. (2018) Controversies in Diagnosis and Management of Kawasaki Disease. World Journal of Clinical Pediatrics, 7, 27-35. https://doi.org/10.5409/wjcp.v7.i1.27
|
[6]
|
Lo, M.S. and Newburger, J.W. (2018) Role of Intravenous Immuno-globulin in the Treatment of Kawasaki Disease. International Journal of Rheumatic Diseases, 21, 64-69. https://doi.org/10.1111/1756-185X.13220
|
[7]
|
Kuo, H.-C., Hsu, Y.-W., Wc, M.-S., et al. (2016) Intravenous Immunoglobulin, Pharmacogenomics, and Kawasaki Disease. Journal of Microbiology, Immunology and Infection, 49, 1-7. https://doi.org/10.1016/j.jmii.2014.11.001
|
[8]
|
Kuo, H.C., Yang, K.D., Chang, W.C., et al. (2012) Kawasaki Disease: An Update on Diagnosis and Treatment. Pediatrics & Neonatology, 53, 4-11. https://doi.org/10.1016/j.pedneo.2011.11.003
|
[9]
|
Muta, H., Ishii, M., Yashiro, M., et al. (2012) Late Intravenous Immunoglobulin Treatment in Patients with Kawasaki Disease. Pediatrics, 129, e291-297. https://doi.org/10.1542/peds.2011-1704
|
[10]
|
Muta, H., Ishii, M., Egami, K., et al. (2004) Early Intravenous Gammaglobulin Treatment for Kawasaki Disease: The Nationwide Surveys in Japan. The Journal of Pediatrics, 144, 496-499. https://doi.org/10.1016/j.jpeds.2003.12.033
|
[11]
|
Rowley, A.H. (2015) The Complexities of the Diagnosis and Management of Kawasaki Disease. Infectious Disease Clinics of North America, 29, 525-537. https://doi.org/10.1016/j.idc.2015.05.006
|
[12]
|
Fujimaru, T., Ito, S., Masuda, H., et al. (2014) Decreased Levels of Inflammatory Cytokines in Immunoglobulin-Resistant Kawasaki Disease after Plasma Exchange. Cytokine, 70, 156-160.
https://doi.org/10.1016/j.cyto.2014.07.003
|
[13]
|
Bayers, S., Shulman, S.T. and Paller, A.S. (2013) Kawasaki Dis-ease: Part II. Complications and Treatment. Journal of the American Academy of Dermatology, 69, 513e1-8. https://doi.org/10.1016/j.jaad.2013.06.040
|
[14]
|
Rahbarimanesh, A., Taghavi-Goodarzi, M., Mohammadinejad, P., et al. (2014) Comparison of High-Dose versus Low-Dose Aspirin in the Management of Kawasaki Disease. Indian Journal of Pediatrics, 81, 1403.
https://doi.org/10.1007/s12098-014-1437-0
|
[15]
|
Dallaire, F., Fortier-Morissette, Z., Blais, S., et al. (2017) Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics, 139, e20170098. https://doi.org/10.1542/peds.2017-0098
|
[16]
|
Ho, L.G.Y. and Curtis, N. (2017) What Dose of Aspirin Should Be Used in the Initial Treatment of Kawasaki Disease. Archives of Disease in Childhood, 102, 1180-1182. https://doi.org/10.1136/archdischild-2017-313538
|
[17]
|
Zhu, F.H. and Ang, J.Y. (2016) The Clinical Diagnosis and Management of Kawasaki Disease: A Review and Update. Current Infectious Disease Reports, 18, 32. https://doi.org/10.1007/s11908-016-0538-5
|
[18]
|
Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.
|
[19]
|
Eleftheriou, D., Levin, M., Shin-gadia, D., et al. (2014) Management of Kawasaki Disease. Archives of Disease in Childhood, 99, 74-83. https://doi.org/10.1136/archdischild-2012-302841
|
[20]
|
Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease: Raise Study, a Randomised, Open-Label, Blinded-Endpoints Trial. The Lancet, 379, 1613-1620. https://doi.org/10.1016/S0140-6736(11)61930-2
|
[21]
|
Singh, S., Sharma, A. and Jiao, F. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment—A Developing Country Perspective. Indian Journal of Pediatrics, 83, 140-145. https://doi.org/10.1007/s12098-015-1890-4
|
[22]
|
Singh, S., Newburger, J.W., Kuijpers, T., et al. (2015) Manage-ment of Kawasaki Disease in Resource-Limited Settings. The Pediatric Infectious Disease Journal, 34, 94-96. https://doi.org/10.1097/INF.0000000000000600
|
[23]
|
Adachi, S., Sakaguchi, H., Kuwahara, T., et al. (2010) High Regression Rate of Coronary Anuerysms Developed in Patients with Immune Globulin Resistant Kawasaki Disease Treated with Steroid Pulse Therapy. The Tohoku Journal of Experimental Medicine, 220, 285-290. https://doi.org/10.1620/tjem.220.285
|
[24]
|
Saneeymehri, S., Baker, K. and So, T.Y. (2015) Overview of Pharma-cological Treatment Options for Pediatric Patients with Refractory Kwasaki Disease. The Journal of Pediatric Phar-macology and Therapeutics, 20, 163-177.
|
[25]
|
Ogata, S., Ogihara, Y., Honda, T., et al. (2012) Corticosteroid Pulse Combination Therapy for Refractory Kawasaki Disease: A Randomized Trial. Pediatrics, 129, e17-e23. https://doi.org/10.1542/peds.2011-0148
|
[26]
|
Chen, S., Dong, Y., Yin, Y., et al. (2013) Intravenous Immuno-globulin plus Corticosteroid to Prevent Coronary Artery Abnormalities in Kawasaki Disease: A Meta-Analysis. Heart, 99, 76-82. https://doi.org/10.1136/heartjnl-2012-302126
|
[27]
|
Weng, K.P., Ou, S.F., Lin, C.C., et al. (2011) Recent Advances in the Treatment of Kawasaki Disease. Journal of the Chinese Medical Association, 74, 481-484. https://doi.org/10.1016/j.jcma.2011.09.001
|
[28]
|
Yu, J.J. (2015) Use of Corticosteroids during Acute Phase of Kawasaki Disease. World Journal of Clinical Pediatrics, 4, 135. https://doi.org/10.5409/wjcp.v4.i4.135
|
[29]
|
Lim, Y.J. and Jung, J.W. (2014) Clinical Outcomes of Initial Dexamethasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawasaki Disease. Yonsei Medical Journal, 55, 1260-1266. https://doi.org/10.3349/ymj.2014.55.5.1260
|
[30]
|
Portman, M.A., Olson, A., Soriano, B., et al. (2011) Etanercept as Adjunctive Treatment for Acute Kawasaki Disease: Study Design and Rationale. American Heart Journal, 161, 494-499. https://doi.org/10.1016/j.ahj.2010.12.003
|
[31]
|
Agarwal, S. and Devendra, K. (2017) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247-258. https://doi.org/10.1080/1744666X.2017.1232165
|
[32]
|
Mori, M., Imagawa, T., Hara, R., et al. (2012) Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-Label Case Series. The Journal of Rheumatology, 39, 864-867. https://doi.org/10.3899/jrheum.110877
|
[33]
|
Tremoulet, A.H., Jain, S., Jaggi, P., et al. (2014) Infliximab for In-tensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 383, 1731-1738.
https://doi.org/10.1016/S0140-6736(13)62298-9
|
[34]
|
Williams, R.V., Wilke, V.M., Tani, L.Y., et al. (2002) Does Abciximab Enhance Regression of Coronary Aneurysms Resulting from Kawasaki Disease. Pediatrics, 109, E4. https://doi.org/10.1542/peds.109.1.e4
|
[35]
|
Choueiter, N.F., Olson, A.K., Shen, D.D., et al. (2010) A Prospective Open Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease. The Journal of Pediatrics, 157, 960-966. https://doi.org/10.1016/j.jpeds.2010.06.014
|
[36]
|
Mori, M., Imagawa, T., Katakura, S., et al. (2004) Efficacy of Plasma Exchange Therapy for Kawasaki Disease Intractable to Intravenous Gamma-Globulin. Modern Rheumatology, 14, 43-47. https://doi.org/10.3109/s10165-003-0264-3
|
[37]
|
Matsui, M., Okuma, Y., Yamanaka, J., et al. (2015) Kawasaki Disease Refractory to Standard Treatments That Responds to a Combination of Pulsed Methylprednisolone and Plasma Exchange: Cytokine Profiling and Literature Review. Cytokine, 74, 339-342. https://doi.org/10.1016/j.cyto.2015.02.014
|
[38]
|
Sonoda, K., Mori, M., Hokosaki, T., et al. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132. https://doi.org/10.1016/j.jpeds.2014.01.020
|
[39]
|
Tremoulet, A.H., Pancoast, P., Franco, A., et al. (2012) Cal-cineurin Inhibitor Treatment of Intravenous Immunoglubulin Resistant Kawasaki Disease. The Journal of Pediatrics, 161, 506-512. https://doi.org/10.1016/j.jpeds.2012.02.048
|
[40]
|
Kuijpers, T.W., Biezeveld, M., Achterhuis, A., et al. (2003) Longstanding Obliterative Panarteritis in Kawasaki Disease: Lack of Cyclosporin A Effect. Pediatrics, 112, 986-992. https://doi.org/10.1542/peds.112.4.986
|
[41]
|
Suzuki, H., Terai, M., Hamada, H., et al. (2011) Cyclosporin A Treatment for Kawasaki Disease Refractory to Initial and Additional Intravenous Immunoglobulin. The Pediatric Infectious Disease Journal, 30, 871-876.
https://doi.org/10.1097/INF.0b013e318220c3cf
|
[42]
|
Aoyagi, R., Hamada, H., Sato, Y., et al. (2015) Study Pro-tocol for a Phase III Multicentre, Randomised, Open-Label, Blinded-End Point Trial to Evaluate the Efficacy and Safety of Immunoglobulin plus Cyclosporin A in Patients with Severe Kawasaki Disease (KAICA Trial). BMJ Open, 5, e009562. https://doi.org/10.1136/bmjopen-2015-009562
|
[43]
|
Rodrigues-Diez, R., González-Guerrero, C., Ocaña-Salceda, C., et al. (2016) Calcineurin Inhibitors Cyclosporine A and Tacrolimus Induce Vascular Inflammation and Endothelial Activation through TLR4 Signaling. Scientific Reports, 6, Article No. 27915. https://doi.org/10.1038/srep27915
|
[44]
|
Al-Homsi, A.S., Roy, T.S., Cole, K., et al. (2015) Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease. Biology of Blood and Marrow Trans-plantation, 21, 604-611.
https://doi.org/10.1016/j.bbmt.2014.08.014
|
[45]
|
Falcini, F. (2006) Kawasaki Disease. Current Opinion in Rheu-matology, 18, 33-38.
https://doi.org/10.1097/01.bor.0000197998.50450.f6
|
[46]
|
Wong, P.T. and Choi, S.K. (2015) Mechanisms and Implications of Dual-Acting Methotrexate in Folate-Targeted Nanotherapeutic Delivery. International Journal of Mo-lecular Sciences, 16, 1772-1790.
https://doi.org/10.3390/ijms16011772
|
[47]
|
Shulman, S.T. (1988) Management of Kawasaki Disease. The Journal of Pediatrics, 113, 1116-1117.
https://doi.org/10.1016/S0022-3476(88)80596-1
|
[48]
|
Lee, M.S., An, S.Y., Jang, G.C., et al. (2002) A Case of In-travenous Immunoglobulin Resistant Kawasaki Disease Treated with Methotrexate. Yonsei Medical Journal, 43, 527-532. https://doi.org/10.3349/ymj.2002.43.4.527
|
[49]
|
Lee, T.J., Kim, K.H., Chun, J.K., et al. (2008) Low-Dose Methotrexate Therapy for Intravenous Immunoglobulin-Resistant Kawasaki Disease. Yonsei Medical Journal, 49, 714-718. https://doi.org/10.3349/ymj.2008.49.5.714
|
[50]
|
Kim, N.Y., Choi, D.Y., Jung, M.J., et al. (2008) A Case of Refractory Kawasaki Disease Complicated by Peripheral Ischemia. Pediatric Cardiology, 29, 1110-1114. https://doi.org/10.1007/s00246-008-9221-4
|
[51]
|
Magalhães, C.M.R., Alves, N.R., Melo, A.V., et al. (2012) Cata-strophic Kawasaki Disease Unresponsive to IVIG in a 3-Month-Old Infant: A Diagnostic and Therapeutic Challenge. Pediatric Rheumatology Online Journal, 10, 28.
https://doi.org/10.1186/1546-0096-10-28
|
[52]
|
《中华儿科杂志》编辑委员会, 中华医学会儿科学分会心血管学组, 中华医学会儿科学分会免疫学组. 川崎病专题讨论会纪要[J]. 中华儿科学杂志, 2007, 45(11): 826-830.
|
[53]
|
梁亚晓, 梁艳萍. 不同剂量丙种球蛋白联合阿司匹林治疗川崎病的临床研究[J]. 泰山医学院学报, 2019, 40(1): 72-74.
|
[54]
|
张艳红. 不同剂量的丙种免疫球蛋白治疗方案对川崎病患儿冠状动脉病变的影响观察[J]. 现代诊断与治疗, 2018, 29(1): 95-96.
|
[55]
|
江佳峪, 赵世权, 高小平. 不同途径给予激素治疗丙种球蛋白无反应型川崎病临床观察[J]. 解放军医药杂志, 2019, 31(1): 63-66.
|
[56]
|
刘卓勋, 温晓莹, 郑燕霞, 等. 川崎病接受首次静脉使用免疫球蛋白标准剂量后病情反应情况与治疗前实验室指标相关性的Meta分析[J]. 中国循证医学杂志, 2018, 18(4): 347-353.
|
[57]
|
何炜星, 张涤. 张涤教授治疗川崎病经验拾萃[J]. 湖南中医药大学学报, 2019, 39(2): 218-221.
|
[58]
|
安娜, 李晨, 段保湘, 等. 中西医结合治疗川崎病疗效评价[J]. 中华中医药学刊, 2017, 35(5): 1310-1312.
|
[59]
|
李小青, 匡琳, 吴俊, 等. 川崎病治疗进展[J]. 现代临床医学, 2016, 42(5): 328-330.
|
[60]
|
郭俊, 沈下贤, 张必利, 等. 介入治疗川崎病并发冠状动脉损害1例并文献回顾[J]. 第二军医大学学报, 2015, 36(11): 1275-1277.
|
[61]
|
张鹏宇, 汤楚中, 潘绪, 等. 英夫利西单抗与 IVIG 治疗 IVIG 初治无效川崎病效果比较[J]. 中国医学前沿杂志(电子版), 2018, 10(5): 60-63.
|
[62]
|
吴洁. 丙种球蛋白无反应型川崎病预测评分系统的验证及血浆置换治疗川崎病269例的系统评价[D]: [硕士学位论文]. 苏州: 苏州大学, 2018.
|